Investigational drugs in clinical trials for Hidradenitis Suppurativa. (2nd January 2018)

• Record Type: Journal Article
• Authors: Theut Riis, Peter; Thorlacius, Linnea R.; Jemec, Gregor B.
• Is Part Of: Expert opinion on investigational drugs. Volume 27:Number 1(2018)
• Page Start: 43
• Page End: 53
• Publication Date: 2018-01-02
• Subjects: Hidradenitis Suppurativa -- Acne Inversa -- CJM112 -- MABp1 -- Apremilast -- IFX- 1 -- Secukinumab -- MEDI8968; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2018.1412430
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Hidradenitis suppurativa is a chronic skin disease with a significant unmet need for treatment options. Randomized controlled trials are few and only a single drug (adalimumab) has Hidradenitis as a registered indication. Areas covered : The clinicaltrials.gov and the EudraCT clinical trials register for reported trials on Hidradenitis Suppurativa was searched on the 22–06-2017. Trials for upcoming new drugs for HS are reported focusing on drugs in phase I and II trials. Expert opinion : Currently, MABp1, Secukinumab, CJM112, Apremilast and IFX-1 are being investigated in Phase I and II trials and offer theoretical and promising new treatment options. A trial with the drug MEDI8968 has been terminated with disappointing results. Metformin, Botulinum Toxin B, Provodine, Benzoyl Peroxide and intralesional triamcinolone are being tested as well. Treatment of Hidradenitis remains a challenge and quality RTCs are needed. Studies indicates a range of potential targets for therapy such as interleukin-1 and interleukin-17, but 'broad-spectrum' immunosuppressants like phosphodiesterase-4 inhibitors are being examined as well. A range of outcomes, including Physician Global Assessment, Sartorius scores and hidradenitis suppurativa clinical response are used in these trials, making future meta-analysis of the data difficult.